# A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors

> **NCT06993116** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SHR-4712 Injection

## Key facts

- **NCT ID:** NCT06993116
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06993116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06993116, "A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06993116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*